Metolazone and Red cell distribution width increased - a phase IV clinical study of FDA data

Summary:

Red cell distribution width increased is reported as a side effect among people who take Metolazone (metolazone), especially for people who are male, 60+ old, also take Tegsedi, and have Hereditary neuropathic amyloidosis.

The phase IV clinical study analyzes which people have Red cell distribution width increased when taking Metolazone. It is created by eHealthMe based on reports of 13,337 people who have side effects when taking Metolazone from the FDA, and is updated regularly.

What is Metolazone?

Metolazone has active ingredients of metolazone. It is often used in swelling. eHealthMe is studying from 13,411 Metolazone users. Check the latest studies of Metolazone.

What is Red cell distribution width increased?

Red cell distribution width increased is found to be associated with 607 drugs and 654 conditions by eHealthMe. Check the latest studies of Red cell distribution width increased.

On Jul, 26, 2026

13,337 people reported to have side effects when taking Metolazone.
Among them, 14 people (0.1%) have Red cell distribution width increased.

Could Metolazone cause Red cell distribution width increased?

Among these 14 people:

What is the gender of people who have Red cell distribution width increased when taking Metolazone? *

female: 45.45 %
male: 54.55 %

What is the age of people who have Red cell distribution width increased when taking Metolazone? *

What are other drugs people take besides Metolazone? *

What are other side effects people have besides Red cell distribution width increased? *

Haematocrit Decreased: 12 people, 85.71%
Haemoglobin Decreased: 12 people, 85.71%
Red Blood Cell Count Decreased: 10 people, 71.43%
Blood Creatinine Increased: 9 people, 64.29%
Blood Urea Increased: 8 people, 57.14%
Thrombocytopenia (decrease of platelets in blood): 7 people, 50.00%
Blood Glucose Increased: 6 people, 42.86%
Glomerular Filtration Rate Decreased: 6 people, 42.86%
White Blood Cell Count Decreased: 6 people, 42.86%
Blood Alkaline Phosphatase Increased: 6 people, 42.86%

What are the existing conditions these people have? *

Hereditary Neuropathic Amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves): 5 people, 35.71%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 21.43%
Amyloidosis (a tumour within which amyloid is produced): 2 people, 14.29%
Pain: 2 people, 14.29%
Muscle Spasms (muscle contraction): 2 people, 14.29%
Infrequent Bowel Movements: 1 person, 7.14%
Arrhythmia Supraventricular (irregular heartbeat supraventricular origin): 1 person, 7.14%
Chronic Kidney Disease: 1 person, 7.14%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 7.14%
Constipation: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Metolazone and have Red cell distribution width increased?

- Check whether Red cell distribution width increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Metolazone:

Metolazone (13,411 reports)

Browse all side effects of Metolazone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red cell distribution width increased:

Red cell distribution width increased (607 drugs)

Browse all the conditions that are associated with Red cell distribution width increased:

Red cell distribution width increased (654 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on metolazone (the active ingredients of Metolazone) and Metolazone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.